Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progress…

TNBC - Triple-Negative Breast CancerBreast Cancer

~Estimated

~$10 – $7,500

Stephen ShiaoNCT07015853

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided te…

TNBC - Triple-Negative Breast CancerMinimal Residual Disease

~Estimated

~$10 – $1,050

Personalis Inc.NCT06230185

← PreviousPage 3 of 3Next →